Article

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Approach

2024-11-27

Abstract excerpt

<h4>Background: </h4> Tumour mutational burden (TMB) is increasingly recognized as a vital biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment. Despite its growing importance, the effectiveness of TMB as a predictive marker is well established in lung cancer and melanoma but remain ambiguous for breast and prostate cancers. <h4>Objective:</h4> This study aims to evaluat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bb8ea1b5-b25c-5775-b9e5-0f519ea6b836
DOI: 10.20944/preprints202411.2060.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachDOI 10.20944/preprints202411.2060.v1Read

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

TMB or not TMB as a biomarker: That is the question.Semantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Semantic proximity Read

Tumour mutational burden: clinical utility, challenges and emerging improvements.Semantic proximity Read

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read